155 related articles for article (PubMed ID: 37039614)
1. In brief: Cardiovascular outcomes with bempedoic acid (Nexletol).
Med Lett Drugs Ther; 2023 Apr; 65(1674):62-63. PubMed ID: 37039614
[No Abstract] [Full Text] [Related]
2. A new indication for bempedoic acid (Nexletol).
Med Lett Drugs Ther; 2024 May; 66(1702):75-77. PubMed ID: 38696311
[No Abstract] [Full Text] [Related]
3. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
[No Abstract] [Full Text] [Related]
4. Inclisiran (Leqvio) for LDL-cholesterol lowering.
Med Lett Drugs Ther; 2022 Mar; 64(1646):43-45. PubMed ID: 35294427
[No Abstract] [Full Text] [Related]
5. Lipid-lowering drugs.
Med Lett Drugs Ther; 2022 Sep; 64(1659):145-152. PubMed ID: 36094548
[No Abstract] [Full Text] [Related]
6. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
[TBL] [Abstract][Full Text] [Related]
8. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
9. Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Bhagavathula AS; Al Matrooshi NO; Clark CCT; Rahmani J
Clin Drug Investig; 2021 Jan; 41(1):19-28. PubMed ID: 33368025
[TBL] [Abstract][Full Text] [Related]
10. Bempedoic Acid: First Approval.
Markham A
Drugs; 2020 May; 80(7):747-753. PubMed ID: 32314225
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
Laufs U; Ballantyne CM; Banach M; Bays H; Catapano AL; Duell PB; Goldberg AC; Gotto AM; Leiter LA; Ray KK; Bloedon LT; MacDougall D; Zhang Y; Mancini GBJ
J Clin Lipidol; 2022; 16(3):286-297. PubMed ID: 35346603
[TBL] [Abstract][Full Text] [Related]
12. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
13. Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia.
Med Lett Drugs Ther; 2021 May; 63(1623):66-67. PubMed ID: 33976097
[No Abstract] [Full Text] [Related]
14. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
Nguyen H; Akamnonu I; Yang T
Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic acid: a promising novel agent for LDL-C lowering.
Agarwala A; Goldberg AC
Future Cardiol; 2020 Sep; 16(5):361-371. PubMed ID: 32463301
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
17. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
18. [Opportunities and perspectives for bempedoic acid use in clinical practice].
Di Fusco SA; Scicchitano P; Colivicchi F
G Ital Cardiol (Rome); 2021 Apr; 22(4 Suppl 1):22S-27S. PubMed ID: 33847315
[TBL] [Abstract][Full Text] [Related]
19. [Bempedoïc acid, new cholesterol-lowering drug].
Scheen AJ; Paquot N; Wallemacq C
Rev Med Liege; 2022 Feb; 77(2):124-131. PubMed ID: 35143133
[TBL] [Abstract][Full Text] [Related]
20. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Bilen O; Ballantyne CM
Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
